ArticleEuropean journal of medical research2025
Association of combined folic acid and progesterone use with congenital malformations in women with vaginal bleeding during early pregnancy: a multicenter cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionProgesterone supplementation is used for miscarriage prevention. Animal studies have showed that folic acid supplementation (FAS) improves progesterone profiles. However, little is known about the interaction between progesterone supplementation and FAS in women with early pregnancy bleeding.
methodsWe conducted a multicenter prospective study of 17,713 women recruited at 11-13 weeks' gestation in 23 tertiary hospitals from 12 provinces in China. The interaction between the treatment (e.g., injection or oral administration of progesterone) and FAS was investigated.
resultsWomen with bleeding in early pregnancy were more likely to have a baby with malformations than those without bleeding (hazard ratio [HR] 1.37; 95% confidence interval [CI] 1.05-1.78; P = 0.0208). Treatment for bleeding was not associated with malformations compared to no treatment (HR, 1.05; 95% CI 0.65-1.72). An insignificant interaction between FAS and progesterone injection was observed in total sample (HR, 1.55, 95% CI 0.19-12.61) and in women with bleeding (HR, 3.22, 95% CI 0.30-34.70). Among women without a history of adverse pregnancy outcomes, progesterone injection was not associated with malformations compared with untreated women (HR, 1.18, 95% CI 0.63-2.22). However, the association approached borderline statistical significance when compared with no bleeding women (HR, 1.61, 95% CI 1.00-2.60, P = 0.051).
conclusionsBleeding in early pregnancy was associated with a higher risk of malformations. The use of progesterone injection should be caution in women without a history of adverse pregnancy outcomes. Further studies are warranted to study the potential interactive effect of FAS and progesterone injection on malformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.